What's Happening?
Nicklaus Children’s Health System is significantly expanding its research capabilities and precision medicine efforts in pediatric oncology. The Helen & Jacob Shaham Cancer & Blood Disorders Institute at Nicklaus Children’s received a $7.5 million appropriation
from the State of Florida through the Cancer Connect Collaborative Research Incubator Fund in 2025. This investment aims to enhance clinical trial capabilities and strengthen the infrastructure to connect more Florida children with advanced treatment options. A major focus is the development of an early-phase pediatric oncology program to expand first-in-child and Phase I/II clinical trials, particularly crucial for children with relapsed, refractory, or rare cancers. The system is also integrating genomics, transcriptomics, proteomics, and microbiome research with drug-sensitivity testing to provide individualized understandings of both the child and the cancer, informing medication selection and dosing. This builds on research by Dr. Maggie Fader, whose study combined genomic profiling with ex vivo drug-sensitivity testing, showing improved progression-free survival in five out of six patients with relapsed or refractory cancers.
Why It's Important?
This expansion is critically important for pediatric oncology in the U.S., particularly in South Florida. Pediatric cancer research often lags behind adult cancer research due to the smaller patient population and unique biological characteristics of childhood cancers. Nicklaus Children’s investment addresses this gap by increasing access to early-phase clinical trials, which are vital for children with limited treatment options. The integration of precision medicine approaches, combining various 'omics' technologies and drug-sensitivity testing, allows for highly individualized treatment plans, potentially leading to better outcomes and reduced toxicity for young patients. This initiative not only provides hope for children and families facing difficult diagnoses but also positions Nicklaus Children’s as a leader in advancing pediatric cancer care. The development of a comprehensive cancer data repository supported by advanced bioinformatics and AI analytics will foster collaboration and accelerate scientific discovery, benefiting the broader medical community and future generations of pediatric cancer patients.
What's Next?
Nicklaus Children’s Health System will continue to develop its early-phase pediatric oncology program, expanding first-in-child and Phase I/II clinical trial capabilities. The institute is also establishing a comprehensive cancer data repository, leveraging advanced bioinformatics and artificial intelligence analytics to manage large volumes of clinical and research data. This infrastructure will facilitate stronger collaboration across Florida and create new academic and industry partnerships focused on pediatric cancer research. Innovation will extend beyond systemic therapy, with ongoing research in areas such as magnetic resonance-guided focused ultrasound for aggressive pediatric brain tumors and advancements in surgical planning for bone and soft-tissue tumors. The institute is also growing physically, with a new home for the Helen & Jacob Shaham Cancer & Blood Disorders Institute under construction on the hospital’s Miami campus. This growth, coupled with national recognition, indicates a sustained commitment to integrating research into clinical care to bring new treatment possibilities to children.
Beyond the Headlines
The advancements at Nicklaus Children’s Health System signify a broader trend in healthcare towards highly personalized and data-driven medicine, particularly for vulnerable populations like pediatric cancer patients. The emphasis on integrating diverse 'omics' data (genomics, transcriptomics, proteomics, microbiome) with drug-sensitivity testing represents a paradigm shift from generalized treatments to therapies precisely tailored to an individual's biological profile. This approach not only improves treatment efficacy but also minimizes the long-term side effects that can be particularly devastating for children. The investment in advanced bioinformatics and AI analytics highlights the increasing reliance on technology to process complex biological data and accelerate research. This could set a precedent for other pediatric institutions, fostering a collaborative ecosystem where data sharing and advanced analytical tools drive breakthroughs. Ultimately, this initiative contributes to a future where pediatric cancer care is not just about survival, but about ensuring a higher quality of life for young survivors.
